Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02144155 · ClinicalTrials.gov registry record · NA
Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia
A NA study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02144155 is a NA study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 14 participants.
The verdict
NCT02144155, a NA study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The Objective of this study is to investigate the long-term efficacy of intranasal oxytocin in improvement of symptoms in patients with schizophrenia who have residual symptoms dispute being on adequate treatment with antipsychotic medication.
Interventions
- DRUG Placebo
- DRUG Oxytocin: 24IU - 168 IU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02144155
The ClinicalTrials.gov registry entry for NCT02144155 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02144155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02144155 about?
NCT02144155 is a clinical study titled "Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia". The Objective of this study is to investigate the long-term efficacy of intranasal oxytocin in improvement of symptoms in patients with schizophrenia who have residual symptoms dispute being on adequate treatment with antipsychotic medication.
What is the current status of trial NCT02144155?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2012-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02144155?
The interventions under investigation include: Placebo (DRUG), Oxytocin: 24IU - 168 IU (DRUG).
Who is sponsoring clinical trial NCT02144155?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.